Alzheimer's Disease Clinical Trials in Phoenix

Showing 81-100 of 237 trials

EPIC: An Intervention for Early-stage AD Dyads - Adapted for Virtual Delivery

NCT03144921

EPIC II (Early-Stage Partners in Care) is a research project designed to assist people with early-stage memory loss and their care partners by providing early-stage related education and skill-training sessions, held via Zoom, designed to reduce stress, enhance well-being, manage challenges, and plan for the future. Researchers will gather feedback from individuals about their experience to continue to improve programs for early-stage memory loss.

DementiaAlzheimer DiseaseMemory Loss

Arizona State University272 participantsStarted Dec 2017

Phoenix, Arizona, United States

TERMINATED< 1 mile

Down Syndrome Clinical Trials - Study of Alzheimer's Disease in Down Syndrome

NCT04149197

The primary objective is to characterize trajectories of change on the primary outcome measures in this study population through longitudinal collection of measures of cognition, function, behavior, and health status.

Alzheimer's Disease in Down Syndrome

LuMind IDSC Foundation252 participantsStarted Jun 2019

Phoenix, Arizona, United States • Irvine, California, United States • La Jolla, California, United States +11 more locations

EPIC: An Intervention for Early-stage AD Dyads - Adapted for Virtual Delivery

Down Syndrome Clinical Trials - Study of Alzheimer's Disease in Down Syndrome

Alzheimer's Disease Trials in Other Cities

TRC-PAD Program: In-Clinic Trial-Ready Cohort

Extension to a Pivotal Study of Sensory Stimulation in Alzheimer's Disease (OLE Hope Study, CA-0015)

Safety and Efficacy Study of Gantenerumab in Participants With Early Alzheimer's Disease (AD)

Synuclein-One Study

Addressing Dementia Via Agitation-Centered Evaluation

SUVN-502 With Donepezil and Memantine for the Treatment of Moderate Alzheimer's Disease- Phase 2a Study

A Study to Evaluate the Safety and Tolerability of Long-term Administration of Gantenerumab in Participants With Alzheimer's Disease (AD)

Assessing Clinical Outcomes in Alzheimer's Disease Agitation

Safety and Efficacy of Piromelatine in Mild Alzheimer's Disease Patients (ReCOGNITION)

Optina Diagnostics' Cerebral ß-Amyloid Status (CAS) Test

A Study of Semorinemab in Patients With Moderate Alzheimer's Disease

Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of TB006 in Participants With Alzheimer's Disease

MK-8189 Safety and Tolerability in Participants With Alzheimer's Disease With or Without Symptoms of Agitation-Aggression and/or Psychosis (MK-8189-017)

Dexmedetomidine in the Treatment of Agitation Associated With Dementia (TRANQUILITY III)

Intranasal Oxytocin for Frontotemporal Dementia

A Study of LY3002813 in Participants With Memory Damage Due to Alzheimer's Disease (AD) or AD

MK-1942/Donepezil Interactions in Participants With Alzheimer's Disease (MK-1942-005)

A Study to Evaluate the Pharmacodynamic (PD) Effects of Once Weekly Administration of Gantenerumab in Participants With Early Alzheimer's Disease (AD)

Other Conditions in Phoenix